Jpmorgan Chase & CO Anavex Life Sciences Corp. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 47,909 shares of AVXL stock, worth $197,385. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,909

Previous 64,436 25.65%

Holding current value

$197,385

Previous $599,000 59.43%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$4.55 - $6.75 $75,197 - $111,557	-16,527 Reduced 25.65%	47,909 $243,000
Q4 2023 Feb 12, 2024	BUY	$5.04 - $9.95 $1,774 - $3,502	352 Added 0.55%	64,436 $599,000
Q3 2023 Nov 14, 2023	BUY	$6.55 - $9.37 $31,426 - $44,957	4,798 Added 8.09%	64,084 $419,000
Q2 2023 Aug 11, 2023	BUY	$7.66 - $9.5 $11,980 - $14,858	1,564 Added 2.71%	59,286 $481,000
Q1 2023 May 18, 2023	BUY	$8.32 - $11.75 $440,743 - $622,444	52,974 Added 1115.71%	57,722 $494,000

Q1 2023 May 11, 2023	SELL	$8.32 - $11.75 $326,360 - $460,905	-39,226 Reduced 89.2%	4,748 $40,000
Q4 2022 Feb 13, 2023	BUY	$7.65 - $14.43 $1,935 - $3,650	253 Added 0.58%	43,974 $407,000
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $26,931 - $38,914	3,026 Added 7.44%	43,721 $452,000
Q2 2022 Aug 11, 2022	SELL	$7.31 - $12.84 $5,738 - $10,079	-785 Reduced 1.89%	40,695 $408,000
Q1 2022 May 11, 2022	BUY	$9.74 - $17.69 $79,293 - $144,014	8,141 Added 24.42%	41,480 $511,000
Q4 2021 Feb 10, 2022	BUY	$16.88 - $23.31 $147,548 - $203,752	8,741 Added 35.54%	33,339 $578,000
Q3 2021 Nov 12, 2021	BUY	$16.82 - $25.75 $413,738 - $633,398	24,598 New	24,598 $440,000

Others Institutions Holding AVXL

# of Institutions

159

Shares Held

31.6M

Call Options Held

910K

Put Options Held

1.35M

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $321M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Anavex Life Sciences Corp. Transaction History